Bifalgorithm post · 10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer

Treatment Combination

Treatment Combination (10 Cancer Treatment Approvals From September 2026 and What They Mean for You · 7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer)…

Ideas in this flowchart

  • All-oral combination for advanced breast cancer
  • Used for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer
  • Intended for disease that has grown after at least one hormone therapy
  • EMBER-3 provided clinical evidence in people with ESR1 mutations
  • Median time before progression was 11.1 months with the combination
  • Median time before progression was 5.5 months with Inluriyo (imlunestrant) alone
Bifalgorithm
Sign up
Feed/

Treatment Combination

No cover

Channel

10 Cancer Treatment Approvals From September 2026 and What They Mean for You

1 page

U
USR292600b83e2a
Ebook2w

"This all-oral combination is for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that has grown after at least one hormone therapy. In EMBER-3, people with ESR1 mutations went a median of 11.1 months before progression on the combination, vs 5.5 months on Inluriyo (imlunestrant) alone."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.